Brokerages Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Target Price at $70.75

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been assigned a consensus rating of “Hold” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $70.75.

Several equities analysts have commented on PBH shares. Canaccord Genuity Group dropped their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Zacks Research downgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Finally, Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a research note on Thursday, May 14th.

Prestige Consumer Healthcare Stock Up 1.8%

Shares of NYSE PBH opened at $47.53 on Friday. The firm has a market cap of $2.25 billion, a price-to-earnings ratio of 12.16, a PEG ratio of 1.50 and a beta of 0.35. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. Prestige Consumer Healthcare has a 52-week low of $42.62 and a 52-week high of $85.29. The business’s 50 day moving average is $51.78 and its two-hundred day moving average is $59.43.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing the consensus estimate of $1.39 by ($0.16). The business had revenue of $281.62 million during the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The business’s revenue was down 5.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Research analysts predict that Prestige Consumer Healthcare will post 4.45 EPS for the current year.

Insider Activity at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the transaction, the vice president owned 42,820 shares in the company, valued at $2,354,671.80. The trade was a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors have recently modified their holdings of PBH. UMB Bank n.a. grew its stake in shares of Prestige Consumer Healthcare by 110.1% during the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after purchasing an additional 219 shares in the last quarter. Bayforest Capital Ltd acquired a new position in shares of Prestige Consumer Healthcare during the fourth quarter worth $29,000. Barrow Hanley Mewhinney & Strauss LLC grew its stake in shares of Prestige Consumer Healthcare by 106.8% during the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock worth $34,000 after purchasing an additional 283 shares in the last quarter. Geneos Wealth Management Inc. grew its stake in shares of Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares in the last quarter. Finally, Torren Management LLC acquired a new position in shares of Prestige Consumer Healthcare during the fourth quarter worth $35,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).